UNSPSC 51113002: Altretamine hydrochloride

This classification denotes an ethylenimine compound with the molecular formula C9H18N6.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30FQ7QG6VM. Most nations, for tariff and trade purposes, schedule altretamine hydrochloride under HS 29336980. As of Q4 2014, ALTRETAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)C1NC(NC(N1)N(C)C)N(C)C.CL.

UNSPSC 51113002 Altretamine hydrochloride is a Commodity code that covers a specific oncology pharmaceutical agent. State and local governments procure this drug primarily through health and human services agencies, corrections departments, and public hospital systems to support cancer treatment programs for eligible beneficiaries. The actual buying activity under this code reflects pharmaceutical procurement tied to state Medicaid programs, employee health plans, and institutional patient care — not direct manufacture or bulk chemical supply. Issuing bodies are predominantly state health departments and human services commissions that manage pharmacy benefit programs and institutional formularies, along with public university hospital systems and county correctional healthcare providers. The procurement approach typically involves competitive bidding for pharmaceutical supply contracts, often structured through group purchasing organizations, wholesaler agreements, or direct manufacturer negotiations as part of broader drug benefit strategy.

The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013) on April 3, 2026, to explore direct-to-manufacturer prescription models and vendor capabilities for implementing a Therapeutic Pharmacy Initiative that would bypass traditional pharmacy benefit managers and wholesalers. This exploratory RFI sought information from vendors about their capacity to support direct contracting, negotiated net pricing arrangements, and value-based agreements with self-insured employer health plans and state agencies. The RFI did not identify specific funding, response deadlines beyond the initial information-gathering phase, or formalized evaluation criteria, signaling that Texas HHS is in early-stage procurement planning before issuing a formal RFP with defined financial parameters and timelines. No other recent state or local opportunities appear in the source materials for this Commodity code.